Kindred Biosciences
Kindred Biosciences is a Burlingame, California veterinary biotechnology company founded in 2012 that develops therapeutic products for companion animals including dogs, cats, and horses. The firm, formerly NASDAQ-listed under KIN, employs 51-100 people and operates as a clinical-stage animal health developer.
- Company typePublic
- Founded1954
- HeadquartersBurlingame, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Kindred Biosciences does
Kindred Biosciences is a veterinary biotechnology company founded in 2012 and headquartered in Burlingame, California, that develops therapeutic products targeting companion animals, specifically dogs, cats, and horses. The company operates as a for-profit entity with a headcount of 51-100 employees and was formerly publicly listed on NASDAQ under the ticker KIN before transitioning to delisted status. Its core business centers on biologic and pharmaceutical R&D for veterinary indications, though the input data does not disclose specific approved products, pipeline assets, or technical platform components.
The company has financed operations primarily through equity capital, raising approximately $62.1M cumulatively across four disclosed rounds from 2012 through 2019, with the largest being a $50M financing led by SLR Capital Partners in October 2019. Earlier rounds included $5.9M in 2013, $1M in 2012, and $5.2M from General American Investors Company in 2017. Leadership is led by founder and CEO Richard Chin, with Steve Galliker serving as CFO, indicating an R&D-intensive operating model typical of clinical-stage animal health developers.
The revenue model is not explicitly disclosed in the input data; no pricing models, customer segments, distribution channels, or named customers are provided. As a veterinary biotech, the implied commercial motion would typically involve FDA Center for Veterinary Medicine approval pathways followed by sales to veterinary hospitals, clinics, and potentially licensing to larger animal health distributors, but no evidence of an executed GTM strategy is available in the source data.
Kindred Biosciences firmographics
Firmographics- Name
- Kindred Biosciences
- Legal name
- Elanco Animal Health Incorporated
- Website
- https://kindredbio.com
- Company type
- Public
- Founded year
- 1954
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Kindred Biosciences is a Burlingame, California veterinary biotechnology company founded in 2012 that develops therapeutic products for companion animals including dogs, cats, and horses. The firm, formerly NASDAQ-listed under KIN, employs 51-100 people and operates as a clinical-stage animal health developer.
- Ownership category
- akta.pro rank
Kindred Biosciences industry classification
Industry- Product category
- Veterinary Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Companion Animal Therapeutics (Rx) (HLAMAEAA)
- akta.pro secondary industries
- Biologics & Immunotherapies (Non-vaccine) (HLAMAEAK), Veterinary Vaccines (Biologics) (HLAMAEAL)
Keywords
Where Kindred Biosciences is headquartered
LocationHeadquarters
- HQ city
- Burlingame
- HQ country
- United States
- HQ region
- North America
Markets served
Kindred Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Kindred Biosciences product offering
Product offeringCore offering
Kindred Biosciences is a veterinary biotechnology company that develops biologic therapies for dogs, cats, and horses. The company's pipeline includes monoclonal antibodies and other recombinant protein therapeutics targeting conditions such as cancer, inflammatory diseases, and metabolic/endocrine disorders in companion and equine animals. Founded in 2012 and headquartered in Burlingame, California, it pursues FDA/CVM-regulated veterinary drug development pathways to bring novel biologics to the animal-health market.
Differentiator
Problem solved
Functional benefit
Brands
- Healthy Purpose: Elanco's corporate sustainability and social impact initiative focused on making life better for animals and people
Products and services
- Veterinary Biologic Therapeutics Pipeline (Dogs, Cats, Horses) Pipeline of biologic therapies — primarily monoclonal antibodies and other recombinant proteins — being developed for diseases in dogs, cats, and horses, including oncology, inflammatory, and metabolic/endocrine indications. Targeted at veterinary clinics and animal hospitals via regulatory (FDA/CVM) approval pathways.
Companies that use Kindred Biosciences
Customer profileIdeal customer profiles2 records
Kindred Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Kindred Biosciences partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights2 records
Kindred Biosciences competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key risks5 records
Key highlights4 records
Customer concentration
Kindred Biosciences social profiles
Digital presenceKindred Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Kindred Biosciences leadership team
Management profileNumber of profiles
Profiles2 records
Kindred Biosciences funding detail
Funding detailFunding overview
Funding rounds4 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Kindred Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Kindred Biosciences
What does Kindred Biosciences do?
Kindred Biosciences is a veterinary biotechnology company that develops biologic therapies for dogs, cats, and horses. The company's pipeline includes monoclonal antibodies and other recombinant protein therapeutics targeting conditions such as cancer, inflammatory diseases, and metabolic/endocrine disorders in companion and equine animals. Founded in 2012 and headquartered in Burlingame, California, it pursues FDA/CVM-regulated veterinary drug development pathways to bring novel biologics to the animal-health market.
Is Kindred Biosciences a public or private company?
Kindred Biosciences is a public company. It is classified as corporate owned and is currently operating.
When was Kindred Biosciences founded?
Kindred Biosciences was founded in 1954. It employs 51 to 100 people.
Where is Kindred Biosciences based?
Kindred Biosciences is headquartered in Burlingame, United States, in the North America region.
Does Kindred Biosciences have an API?
No public API is recorded for Kindred Biosciences.
What industry is Kindred Biosciences in?
Kindred Biosciences's product category is Veterinary Biopharmaceuticals. Its primary akta.pro industry code is HLAMAEAA, Companion Animal Therapeutics (Rx), with a secondary code of HLAMAEAK, Biologics & Immunotherapies (Non-vaccine). Its NAICS code is 325414 and its SIC code is 2834.